Ineffectiveness of certain commercial prothrombin complex concentrates in treatment of patients with inhibitors of factors VIII and IX.
Explore the source record for details and available documents.
SEARCH · PubMed Health
Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
FEIBA and Autoplex T have been used to control bleeding in patients with factor VIII or IX inhibitors for over 25 years. The major components of FEIBA are thought to be activated factor X and prothrombin, whereas the main active components in Autoplex T are thought to be activated factors IX and VII. Both products have been found to effectively control approximately 80% of bleeds involving joints and soft tissues. Published experience of their use in surgery is limited. Thrombotic complications have been reported with high dose FEIBA therapy and have led to maximum dosage guidelines for this product.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.